Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Pirtobrutinib for BTKi Pretreated CLL
Open-label, randomized, phase III study [BRUIN CLL-321] Relapsed/refractory CLL/SLL, previously treated with BTKi Pirtobrutinib (n=119) vs investigator's choice of Idelalisib/Ritux
New Reference: Nivolumab and Ipilimumab for Advanced Gastric Cancer
Single-arm phase II study [NO LIMIT, WJOG13320G]. Microsatellite instability-high advanced gastric or esophagogastric junction cancer. Nivolumab (240 mg every 2 weeks) plus low-dos
New Reference: Adagrasib for kRAS Mutated NSCLC
Randomised, open-label, phase 3 trial [KRYSTAL-12] Advanced NSCLC with KRASG12C mutation, previously treated with chemotherapy and immunotherapy 600 mg adagrasib twice daily (n=301
New Drug: Linvoseltamab for Relapsed/Refractory Myeloma
Phase I/II, first-in-human trial Relapsed/refractory multiple myeloma Livoseltamab 50mg (n=104) vs 200mg (n=117)
New Reference: Retifanlimab + Chemotherapy for Advanced Anal Cancer
Randomised, double-blind, phase 3 trial [POD1UM-303/InterAACT-2]. Patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal, aged >=18, ECO
New Indication: Periop Pembrolizumab for Head and Neck Cancer
Phase 3, open-label, randomized, multicenter trial [KEYNOTE-689] Locally advanced resectable head and neck squamous-cell carcinoma (HNSCC) Neoadjuvant and adjuvant pembrolizumab pl
New Reference: Neoadjuvant Nivolumab for NSCLC
Randomized, open-label, phase 3 trial [CheckMate 816] Resectable stage IB to IIIA NSCLC Nivolumab+chemotherapy (n=179) vs chemotherapy (n=179) for 3 cycles followed by surgery
New Protocol: Perioperative Durvalumab with FLOT in Gastric Cancer
Phase 3, multinational, double-blind, randomized trial [MATTERHORN] Resectable gastric or gastroesophageal junction adenocarcinoma Durvalumab (n=474) vs Placebo (n=474) every 4 wee
New Reference: MRD-Guided CLL Treatment
Phase 3, multicenter, open-label trial [FLAIR ISRCTN01844152] Previously untreated chronic lymphocytic leukemia (CLL) patients Ibrutinib-venetoclax vs. Ibrutinib alone vs. Fludarab
